[{"data":1,"prerenderedAt":34},["ShallowReactive",2],{"$fngqGFAylFGSskiQn79mUj-OMnVxdqxq1XM1FnNSBdPw":3},{"code":4,"show":5,"msg":6,"data":7,"status":33},1,0,"",{"info":8,"next":19,"prev":25,"others":30},{"cate_name":9,"id":10,"cid":4,"title":11,"desc":12,"title_cn":13,"desc_cn":14,"content_cn":15,"image":16,"content":17,"is_show":4,"home_recommend":4,"publish_at":18},"科技",3,"First Patient In! SciBrunch Initiates Phase I Clinical Trial of Highly Selective PARP1 Inhibitor SPR1020","SciBrunch Therapeutics announced that the Phase I/II clinical trial of SPR1020 for advanced solid tumors, co-led by the Cancer Hospital of the Chinese Academy of Medical Sciences and Harbin Medical","首例患者入组！思璞锐启动高选择性PARP1抑制剂SPR1020临床I期试验","上海思璞锐医药科技有限公司（SciBrunch Therapeutics，简称“思璞锐”）宣布由中国医学科学院肿瘤医院（简称“医肿”）与哈尔滨医科大学附属肿瘤医院（简称“哈肿”）两家组长单位共同牵头的SPR1020治疗晚期实体瘤的I/II期临床研究已在哈肿顺利启动，并于2026年1月8日成功完成首例受试者给药。这标志着SPR1020药物的临床开发迈出关键一步，也为相关患者带来了新的治疗希望。","\u003Cp>上海思璞锐医药科技有限公司（SciBrunch Therapeutics，简称“思璞锐”）宣布由中国医学科学院肿瘤医院（简称“医肿”）与哈尔滨医科大学附属肿瘤医院（简称“哈肿”）两家组长单位共同牵头的SPR1020治疗晚期实体瘤的I/II期临床研究已在哈肿顺利启动，并于2026年1月8日成功完成首例受试者给药。这标志着SPR1020药物的临床开发迈出关键一步，也为相关患者带来了新的治疗希望。\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https://api-scibrunch.hellokoma.com/uploads/images/20260430/202604301151480779b0348.png\" alt=\"\" data-href=\"\" style=\"width: 404.38px;height: 120.47px;\">\u003C/p>\u003Cp style=\"text-align: center;\">\u003Cbr>\u003C/p>\u003Cp style=\"text-align: left;\">这是一项评估SPR1020用于治疗晚期实体瘤成人患者的多中心、开放性研究。本研究旨在评价SPR1020单药治疗在晚期实体瘤成人患者中的安全性、耐受性、药代动力学特征和初步抗肿瘤效果。该临床试验于2025年12月获得中国国家药品监督管理局（NMPA）的临床试验批准。SPR1020是一种高选择性PARP1抑制剂，具有透脑性强和靶点选择性高的显著优势。临床前研究显示，SPR1020能精准作用于PARP1靶点，在保证疗效的同时降低血液毒性风险，展现出成为同类最优创新疗法的巨大潜力。\u003C/p>\u003Cp style=\"text-align: left;\">\u003Cbr>\u003C/p>\u003Ch3 style=\"text-align: start;\">\u003Cspan style=\"font-size: 19px;\">\u003Cstrong>哈肿乳腺内科主任蔡莉教授对试验启动和首例给药表示了祝贺：\u003C/strong>\u003C/span>\u003C/h3>\u003Cp>SPR1020药物基于其独特的高选择性与透脑特性，为解决当前临床治疗困境提供了新的可能。在刘通副院长大力支持下，我们团队很高兴参与到这项具有潜力的临床研究中。试验的顺利启动与快速推进，也离不开研究中心同事们的专业与敬业。我们将秉持科学、规范的原则，携手扎实稳妥地推进临床研究，以期早日为患者带来新的治疗选择。\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3 style=\"text-align: start;\">\u003Cspan style=\"font-size: 19px;\">\u003Cstrong>医肿肿瘤内科治疗中心主任马飞教授也对项目进展表示了祝贺：\u003C/strong>\u003C/span>\u003C/h3>\u003Cp>我们密切关注SPR1020临床试验的进展，祝贺项目顺利启动并完成首例给药。该药物在靶点选择性和透脑性方面展现的设计优势令人印象深刻，我们期待很快正式启动本中心的临床试验工作，与各方共同努力，加速推进这一具有潜力的创新药物的临床开发进程。\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3 style=\"text-align: start;\">\u003Cspan style=\"font-size: 19px;\">\u003Cstrong>思璞锐创始人CEO胡滔博士表示：\u003C/strong>\u003C/span>\u003C/h3>\u003Cp>我们衷心感谢研究者、患者及家属与各合作方的专业付出与支持，以及公司临床团队在获得临床试验批件后为本次试验的高质量快速推进做出的努力。SPR1020展现出的高选择性、高活性及高透脑特性，源于我们对靶点的深刻理解与理性药物设计。思璞锐将紧密跟进临床数据，全力探索其成为同类最佳药物的潜力。未来思璞锐将继续保持高效研发节奏，加速推动该药物早日惠及全球患者。\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3 style=\"text-align: start;\">\u003Cspan style=\"font-size: 19px;\">\u003Cstrong>关于药物SPR1020\u003C/strong>\u003C/span>\u003C/h3>\u003Cp>SPR1020是一种口服、高选择性、具有透脑能力，并且为非P-糖蛋白（P-gp）底物的PARP1小分子抑制剂。临床前研究表明，其在选择性及穿透血脑屏障方面均表现优异，有望为存在未满足临床需求的疾病领域提供新的治疗选择。\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3 style=\"text-align: start;\">\u003Cspan style=\"font-size: 19px;\">\u003Cstrong>关于思璞锐（SciBrunch Therapeutics）\u003C/strong>\u003C/span>\u003C/h3>\u003Cp style=\"text-align: start;\">思璞锐是一家专注于小分子抗肿瘤药物迭代创新的研发型生物技术公司。公司以新视角挖掘临床验证靶点开发潜力，前瞻性地进行差异化的产品性能设计，秉承“极致”与“高效”的理念，打造具有全球竞争力的产品管线。\u003C/p>\u003Cp style=\"text-align: start;\">\u003Cbr>\u003C/p>\u003Cp style=\"text-align: start;\">公司由资深连续创业者胡滔博士携手药物化学专家张杨博士共同创立，并于2025年6月完成超2亿元天使轮融资，由知名医疗健康投资机构博远资本和汉康资本联合领投，骊宸投资和LongRiver江远投资参与跟投。\u003C/p>","https://api-scibrunch.hellokoma.com/uploads/images/20260416/202604161535589162c2350.jpg","\u003Cp>\u003Cspan style=\"font-family: Arial;\">SciBrunch Therapeutics\u003C/span> \u003Cspan style=\"font-family: Arial;\">announced that the Phase I/II clinical trial of SPR1020 for advanced solid tumors, co-led by the Cancer Hospital of the Chinese Academy of Medical Sciences and Harbin Medical University Cancer Hospital as the two leading sites, has been successfully initiated at Harbin Medical University Cancer Hospital. The first patient was dosed on January 8, 2026, marking a key milestone in the clinical development of SPR1020 and bringing new therapeutic hope to patients.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">This is a multicenter, open-label study evaluating SPR1020 in adult patients with advanced solid tumors. The study aims to assess the safety, tolerability, pharmacokinetic profile, and preliminary anti-tumor activity of SPR1020 as a monotherapy. The clinical trial was approved by the National Medical Products Administration (NMPA) in December 2025.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">SPR1020 is a highly selective PARP1 inhibitor with significant advantages in potent brain penetration and high target selectivity. Preclinical studies demonstrate that SPR1020 acts precisely on the PARP1 target, reducing the risk of hematologic toxicity while maintaining efficacy, showing strong potential to become a best-in-class innovative therapy.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch2>\u003Cstrong>About SPR1020\u003C/strong>\u003C/h2>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">SPR1020 is an oral, highly selective, brain-penetrating small-molecule PARP1 inhibitor that is not a substrate for P-glycoprotein (P-gp). Preclinical studies show its excellent performance in selectivity and blood-brain barrier penetration, promising new treatment options for areas with unmet medical needs.\u003C/span>\u003C/p>",1767936313,{"publish_time":20,"id":21,"title":22,"title_cn":23,"publish_at":24},"2026-01-30",4,"SciBrunch Therapeutics Completes Over $35 Million Pre-A Round Financing, Totaling $65 Million in Two Recent Rounds","思璞锐SciBrunch完成超3500万美元Pre-A轮融资，近期两轮融资合计6500万美元",1769702400,{"publish_time":26,"id":4,"title":27,"title_cn":28,"publish_at":29},"2025-06-05","SciBrunch Therapeutics Completes Over RMB 200 Million Angel Round Financing, Focused on Innovative Small-Molecule Oncology Drugs","思璞锐完成超2亿元天使轮融资，专注小分子抗肿瘤创新药开发",1749101112,[31,32],{"publish_time":20,"id":21,"title":22,"title_cn":23,"publish_at":24},{"publish_time":26,"id":4,"title":27,"title_cn":28,"publish_at":29},200,1778239543633]